Alvotech (ALVO) Income from Continuing Operations (2021 - 2026)
Alvotech (ALVO) posted Income from Continuing Operations of 79000.0 for Q1 2026, down 99.97% on a QoQ basis from 299898000.0 in Q4 2025, and down 99.93% year-over-year from 109921000.0 in Q1 2025.
Alvotech (ALVO) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Alvotech's Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 79000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 99.93% year-over-year to 79000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 26506000.0 (up 109.76% YoY) and the FY2025 annual result came in at 27919000.0, up 111.31% from the prior year.
- Income from Continuing Operations was 79000.0 for Q1 2026 at Alvotech, down from 299898000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 299898000.0 in Q4 2025 and bottomed at 651135000.0 in Q4 2023.
- A 5-year average of 89142941.18 and a median of 275532.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 370.11% — and 2025, when it jumped 50166.73%.
- Alvotech's Income from Continuing Operations stood at 557758000.0 in 2022, then dropped by 16.74% to 651135000.0 in 2023, then soared by 66.48% to 218253000.0 in 2024, then soared by 237.41% to 299898000.0 in 2025, then plunged by 99.97% to 79000.0 in 2026.
- Business Quant data shows ALVO's Income from Continuing Operations at 79000.0 in Q1 2026, 299898000.0 in Q4 2025, and 308702000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Alvotech | 935.87 Mn | 935.87 Mn | 5.09 Mn | 79,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 79,000.00 |
| Dec 31, 2025 | 299.90 Mn |
| Sep 30, 2025 | -308.70 Mn |
| Jun 30, 2025 | 35.23 Mn |
| Mar 31, 2025 | 109.92 Mn |
| Dec 31, 2024 | -218.25 Mn |
| Sep 30, 2024 | -316.93 Mn |
| Jun 30, 2024 | 153.60 Mn |
| Mar 31, 2024 | -219,549.00 |
| Dec 31, 2023 | -651.14 Mn |
| Aug 31, 2023 | -136.71 Mn |
| Jun 30, 2023 | 88.65 Mn |
| Mar 31, 2023 | -275,532.00 |
| Dec 31, 2022 | -557.76 Mn |
| Aug 31, 2022 | -201.54 Mn |
| Jun 30, 2022 | 265.78 Mn |
| Mar 31, 2022 | -77.06 Mn |
| Dec 31, 2021 | 206.49 Mn |
| Sep 30, 2021 | -55.83 Mn |